We are live on ! Find out more
AIP

Arrowpoint Investment Partners Portfolio holdings

AUM $113M
1-Year Est. Return 73.91%
This Fund
S&P 500
This Quarter Est. Return
+4.97%
1 Year Est. Return
+73.91%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$679M
AUM Growth
+$579M
Cap. Flow
+$572M
Cap. Flow %
84.27%
Top 10 Hldgs %
73.8%
Holding
153
New
75
Increased
18
Reduced
9
Closed
49

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$81.9M
2
MSFT icon
Microsoft
MSFT
+$72.7M
3
JNJ icon
Johnson & Johnson
JNJ
+$62.1M
4
HD icon
Home Depot
HD
+$57.4M
5
QCOM icon
Qualcomm
QCOM
+$53.6M

Top Sells

Rank Stock Value
1
ECHO
EchoStar
ECHO
+$3.77M
2
ALAB icon
Astera Labs
ALAB
+$3.4M
3
VCSH icon
Vanguard Short-Term Corporate Bond ETF
VCSH
+$3.07M
4
HSAI
Hesai Group
HSAI
+$1.85M
5
FIX icon
Comfort Systems
FIX
+$1.76M

Sector Composition

Rank Sector Weight
1 Technology 42.95%
2 Healthcare 17.88%
3 Consumer Discretionary 14.6%
4 Financials 13.87%
5 Communication Services 0.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
76
Spyre Therapeutics
SYRE
$9.27B
$450K 0.07%
+13,724
New +$359K
GOOGL icon
77
Alphabet (Google) Class A
GOOGL
$4.33T
$438K 0.06%
+1,400
New +$400K
XLI icon
78
State Street Industrial Select Sector SPDR ETF
XLI
$34.5B
$434K 0.06%
2,800
+1,700
+155% +$262K
RYAAY icon
79
Ryanair
RYAAY
$30.9B
$389K 0.06%
5,387
-21,225
-80% -$1.38M
WRBY icon
80
Warby Parker
WRBY
$3.21B
$389K 0.06%
+17,843
New +$388K
AXSM icon
81
Axsome Therapeutics
AXSM
$11.3B
$385K 0.06%
+2,110
New +$295K
IMVT icon
82
Immunovant
IMVT
$8.17B
$349K 0.05%
+13,714
New +$306K
VCSH icon
83
Vanguard Short-Term Corporate Bond ETF
VCSH
$45B
$327K 0.05%
4,100
-38,500
-90% -$3.07M
NVST icon
84
Envista
NVST
$4.52B
$319K 0.05%
+14,700
New +$302K
TWST icon
85
Twist Bioscience
TWST
$7.76B
$317K 0.05%
+9,992
New +$312K
SOXX icon
86
iShares Semiconductor ETF
SOXX
$45.2B
$301K 0.04%
+1,000
New +$295K
CYTK icon
87
Cytokinetics
CYTK
$10.5B
$285K 0.04%
+4,480
New +$279K
DYN icon
88
Dyne Therapeutics
DYN
$4.94B
$281K 0.04%
+14,383
New +$272K
APLS
89
DELISTED
Apellis Pharmaceuticals
APLS
$271K 0.04%
+10,806
New +$254K
ACAD icon
90
Acadia Pharmaceuticals
ACAD
$5.06B
$267K 0.04%
+10,011
New +$239K
COGT icon
91
Cogent Biosciences
COGT
$7.07B
$261K 0.04%
7,353
-8,745
-54% -$246K
VTYX
92
DELISTED
Ventyx Biosciences
VTYX
$257K 0.04%
28,453
+1,595
+6% +$11.9K
RVMD icon
93
Revolution Medicines
RVMD
$44B
$255K 0.04%
3,200
-1,189
-27% -$78K
TERN
94
DELISTED
Terns Pharmaceuticals
TERN
$240K 0.04%
+5,931
New +$137K
MLYS icon
95
Mineralys Therapeutics
MLYS
$2.38B
$232K 0.03%
+6,384
New +$256K
BBIO icon
96
BridgeBio Pharma
BBIO
$16.6B
$224K 0.03%
+2,925
New +$192K
CRNX icon
97
Crinetics Pharmaceuticals
CRNX
$8.93B
$220K 0.03%
+4,717
New +$210K
MDGL icon
98
Madrigal Pharmaceuticals
MDGL
$11.9B
$216K 0.03%
371
-421
-53% -$215K
NKTR icon
99
Nektar Therapeutics
NKTR
$2.53B
$208K 0.03%
+4,927
New +$276K
ABVX
100
Abivax
ABVX
$11.2B
$200K 0.03%
+1,485
New +$162K
2 3
4
5 6

Similar funds

VCM
Veradace Capital Management Dallas, Texas $112M AUM
TBNY
Trustco Bank (New York) Albany, New York $113M AUM 34.59% 1-Year Est. Return
UOWF
University of Wisconsin Foundation Madison, Wisconsin $113M AUM 23.15% 1-Year Est. Return
PC
Parrish Capital Kennesaw, Georgia $112M AUM
MC
Matters Capital Miami, Florida $113M AUM
ML
MSRH LLC New York $113M AUM
DM
Diker Management New York $112M AUM 59.78% 1-Year Est. Return
APFP
Action Point Financial Planning Grand Rapids, Michigan $112M AUM

Arrowpoint Investment Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Arrowpoint Investment Partners held 153 positions worth $679M, up 578% from $100M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Arrowpoint Investment Partners deployed $572M of net new capital in Q4 2025, opening 75 new positions and adding to 18 existing holdings. Its largest new stake was Microsoft: 145,000 shares worth $70.1M.

By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 7.7% a quarter earlier, followed by Healthcare and Consumer Discretionary.

On the sell side, the largest reduction was Vanguard Short-Term Corporate Bond ETF, an estimated $3.07M trimmed.

  • Arrowpoint Investment Partners's largest Q4 2025 buy was Microsoft: 145,000 shares worth $70.1M.
  • Arrowpoint Investment Partners added most to NVIDIA in Q4 2025, an estimated $81.9M increase.
  • Arrowpoint Investment Partners's biggest Q4 2025 reduction was Vanguard Short-Term Corporate Bond ETF, cutting an estimated $3.07M.
  • Arrowpoint Investment Partners fully exited EchoStar in Q4 2025, selling an estimated $3.77M.
  • Arrowpoint Investment Partners's ten largest holdings make up 74% of its $679M portfolio in Q4 2025.
  • Arrowpoint Investment Partners opened 75 new positions and closed 49 in Q4 2025.
  • Arrowpoint Investment Partners's portfolio value rose 578% quarter-over-quarter to $679M.

Based on Arrowpoint Investment Partners's 13F filing for Q4 2025, filed 11 Feb 2026.